Search the Newsreel

Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) recently surpassed Q2 revenue expectations by 66% and reported a smaller loss per share than anticipated, leading analysts to upgrade revenue estimates and reduce loss projections for 2026. The company's stock also saw a 15% increase in its price target …

Mark Mossler (CCCC) files to sell 15,000 shares after recent stock sales

Mark Mossler has filed a Form 144 to sell 15,000 shares of C4 Therapeutics, Inc. (CCCC) common stock, acquired through a stock option exercise. The aggregate market value of this planned sale is $61,072.50, and the transaction is expected to occur on or after …

Brokers Set Expectations for C4 Therapeutics Q3 Earnings

Brookline Capital Markets has adjusted its Q3 2026 EPS estimate for C4 Therapeutics (NASDAQ: CCCC) to a loss of $0.20 per share, an improvement from its previous forecast. This revision follows C4 Therapeutics' recent earnings report where it surpassed analyst expectations with a loss …

C4 Therapeutics, Inc. $CCCC Shares Bought by Wasatch Advisors LP

Wasatch Advisors LP increased its stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 18.9% in the second quarter, now owning 3.52 million shares valued at $16.45 million. Institutional investors collectively own 78.81% of the company. C4 Therapeutics recently reported a smaller-than-expected quarterly loss and exceeded …

Wells Fargo Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $10

Wells Fargo has reaffirmed its Buy rating for C4 Therapeutics (CCCC.US), holding its target price at $10. This indicates the firm's continued confidence in the company's stock performance.

C4 Therapeutics (CCCC) Form 144 shows planned 19,519-share sale after option exercise

A holder of C4 Therapeutics, Inc. (CCCC) common stock has filed a Form 144 notice indicating a planned sale of up to 19,519 shares, with an aggregate market value of $76,680.39. This sale is connected to a stock option exercise for cash, expected on …

C4 Therapeutics (CCCC): Morgan Stanley reports 8.0% beneficial ownership stake

Morgan Stanley has reported an updated beneficial ownership stake in C4 Therapeutics, Inc. (CCCC) through a Schedule 13G/A filing. The firm now beneficially owns 8,862,002 shares, representing 8.0% of the outstanding common stock. This includes shares held by Morgan Stanley Capital Services LLC and …

C4 Therapeutics Releases Q2 2026 Financial Results

C4 Therapeutics (CCCC) reported its Q2 2026 financial results, showing a narrower loss per share of $0.18, a 51.4% improvement year-over-year. The biopharmaceutical company generated $6.6 million in revenue and a net loss of $23.6 million as it continues to invest in its protein …

FY2029 EPS Estimates for C4 Therapeutics Cut by Analyst

Brookline Capital Markets has reduced its FY2029 EPS estimate for C4 Therapeutics (NASDAQ: CCCC) to $5.90 from $6.14, while forecasting $22.46 for FY2030. This adjustment comes despite C4 Therapeutics beating quarterly expectations with an EPS loss of $0.18 against a $0.23 consensus and revenue …

Is C4 Therapeutics Inc (CCCC) Overvalued After Q2 Earnings Revea

Form 8K C4 Therapeutics Inc For: 11 August By Investing.com

This article reports on a Form 8K filing by C4 Therapeutics Inc for August 11. The brief mention indicates a financial disclosure event for the company, common for publicly traded entities. The content primarily serves as a placeholder announcement from Investing.com.

C4 Therapeutics Q2 Results: Sales beat estimates by 66 percent

C4 Therapeutics (NASDAQ:CCCC) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

C4 Therapeutics (NASDAQ:CCCC) recently announced its quarterly earnings, surpassing analyst estimates by reporting a loss of $0.18 per share against an expected $0.23 loss, and generating $6.64 million in revenue, exceeding the $4.00 million consensus. Despite beating estimates, the company remains unprofitable with significant …

C4 Therapeutics Submits Q2 2026 Form 10-Q to SEC Detailing Financials and Collaborations

C4 Therapeutics, Inc. (NASDAQ:CCCC) officially filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026. This report covers the financial period that ended on June 30, 2026, providing detailed insights into the company's financials and collaborative …

CCCC Looks 81.0% Overvalued on GF Value™

C4 Therapeutics Inc (NASDAQ: CCCC) reported strong Q2 revenues, surpassing analyst expectations, but its stock appears significantly overvalued according to GuruFocus' GF Value™ metric, which places its intrinsic value 81.0% below the current trading price. The company's GF Score™ of 51/100 indicates strong momentum …

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics reports Q2 2026: $6.6M revenue, $23.6M net loss, $300.4M cash

C4 Therapeutics reported its second-quarter 2026 financial results, with revenues reaching $6.6 million and a net loss of $23.6 million. The company holds $300.4 million in cash, which is expected to fund operations through the end of 2028, and highlighted progress in its cemsidomide …

C4 Therapeutics, Inc. 2026: Revenue $6.64M, EPS ($0.18) — 10-Q Summary

C4 Therapeutics, Inc. reported its 2026 financial results, showing revenue of $6.64 million, a 2.8% increase year-over-year, and a diluted EPS of ($0.18), a significant improvement from ($0.37) in the prior year. The company highlighted ongoing clinical progress with cemsidomide, pipeline prioritization for CFT8919, …

C4 Therapeutics Q2 Revenue Rises to $6.6 Million

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc. (C4T) announced an inducement grant of non-qualified stock options to purchase 162,880 shares of its common stock for a new employee. This grant, made on August 10, 2026, aligns with Nasdaq Listing Rule 5635(c)(4) and is designed to attract new talent. …

C4 Therapeutics Inc (CCCC) Stock News Today

C4 Therapeutics, Inc. Stock 12‑Month Price Target Cut to $13.2, Implies 263% Upside

C4 Therapeutics, Inc. (CCCC) has seen its average 12-month price target reduced slightly from $13.33 to $13.2 by five analysts, with individual forecasts ranging from $7 to $30 per share. This new target suggests a significant 263% potential upside from its August 6 closing …

C4 Therapeutics Inc (CCCC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for C4 Therapeutics Inc (CCCC), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 7 analysts, the stock has a "Buy" trend with an average price target of $10.00, suggesting a significant upside. …

Renaissance Technologies LLC Increases Stock Holdings in C4 Therapeutics, Inc. $CCCC

Renaissance Technologies LLC significantly increased its stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 53.6% in the first quarter, now owning 2.23% of the company. Other institutional investors have also adjusted their positions, with hedge funds and institutional investors collectively holding 78.81% of the stock. …

C4 Therapeutics, Inc expected to post a loss of 23 cents a share - Earnings Preview

C4 Therapeutics, Inc. is anticipated to report a loss of 23 cents per share, according to this earnings preview. The company's financial performance will be closely watched as it releases its upcoming earnings report.

C4 Therapeutics Stock Price Forecast. Should You Buy CCCC?

C4 Therapeutics (CCCC) to Announce Earnings on Thursday

CCCC|C4 Therapeutics Inc|Price:3.540|Chg%:-0.050

C4 Therapeutics Inc. (CCCC) is a clinical-stage biopharmaceutical company focusing on targeted protein degradation for difficult-to-treat diseases, particularly in oncology. Its stock is currently trading at $3.515, with a market cap of $260.72M. Analysts rate the stock as a "Buy" with a target price …

C4 Therapeutics Inc (CCCC) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of C4 Therapeutics Inc (CCCC), noting its stable financial status and low operational efficiency. The company's financial score is 6.09, placing it 288th out of 386 in the Biotechnology & Medical Research industry. It also highlights a …

C4 Therapeutics Inc (CCCC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for C4 Therapeutics Inc (CCCC), noting its current valuation score of 7.38 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not …

C4 Therapeutics Inc (CCCC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of C4 Therapeutics Inc (CCCC), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The data includes …

C4 Therapeutics Inc (CCCC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of C4 Therapeutics Inc (CCCC) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years. The page also presents current stock performance data, including its …

C4 Therapeutics, Inc. Revenue Breakdown – NASDAQ:CCCC

C4 Therapeutics, Inc. reported a total revenue of $35.95 million USD last year. The entirety of this revenue was generated from its Targeted Protein Degradation segment, marking a slight increase from $35.58 million USD the previous year. All of the company's revenue came from …